Research On The Correlation Between S100A8 And The Efficacy Of Neoadjuvant Chemotherapy In Breast Cancer

ObjectiveIn this experiment,93 patients with neoadjuvant chemotherapy for breast cancer who met the inclusion criteria and were confirmed by hollow needle aspiration in Zhejiang Cancer Hospital and Zhejiang Tongde Hospital from 2014 to 2019 were retrospectively analyzed.They received EC→T regimen neoadjuvant chemotherapy,and then underwent surgical treatment.Immunohistochemical method was used to detect the protein expression of S100A8 gene in hollow needle puncture samples before chemotherapy,and analyze the relationship between S100A8 and the efficacy of neoadjuvant chemotherapy.To study the correlation between S100A8 and clinical characteristics,the expression status and molecular typing of ER,PR,HER-2,Ki67 and other biomarkers.Multi variate Logistic analysis was performed to determine whether S100A8,ER,PR,HER-2 and Ki67 could be independent predictors of the efficacy of neoadjuvant chemotherapy for breast cancer.MethodsIn this study,93 patients with neoadjuvant chemotherapy for breast cancer who met the inclusion criteria and were confirmed by hollow needle aspiration in Zhejiang Cancer Hospital and Zhejiang Litongde Hospital from 2014 to 2019 were retrospectively analyzed.They received EC sequential T regimen neoadjuvant chemotherapy,and then underwent surgical treatment.Immunohistochemical method was used to detect the protein expression of S100A8 gene in hollow needle puncture samples before chemotherapy,and analyze the relationship between S100A8 and the efficacy of neoadjuvant chemotherapy.To study the correlation between S100A8 and clinical characteristics,the expression status and molecular typing of ER,PR,HER-2,Ki67 and other biomarkers.Multivariate Logistic analysis was performed to determine whether S100A8,ER,PR,HER-2 and Ki67 could be independent predictors of the efficacy of neoadjuvant chemotherapy for breast cancer.Results1.A total of 93 breast cancer patients who met the criteria were included in this study and all received 4 to 8 courses of EC sequential T chemotherapy before surgery.After the completion of neoadjuvant chemotherapy,the clinical evaluation showed that 65 patients had clinically effective efficacy(CR+PR),with a clinical effective rate of 69.9%,22 patients with SD(23.7%),6 patients with PD(6.5%),and no clinical efficacy(SD+PD)of 30.1%.Postoperative pathological complete response(PCR)was achieved in 16 patients with a PCR rate of 17.2%.2.Among the 93 samples in this study,37 cases(37/93,44.1%)were positive for S100A8 expression,including 31 cases(31/37,83.7%)with clinical effectiveness,56 cases(34/56,60.7%)with negative S100A8 expression.The differences in clinical chemotherapy efficacy evaluation of breast cancer samples with different S100A8 expression states were statistically significant(P<0.05).Among the samples with positive S100A8 expression,10 cases(10/37,27.0%)could achieve postoperative PCR pathological results,and 6 cases(6/56,10.7%)could achieve postoperative PCR pathological results in the samples with negative S100A8 expression.The pCR rate of breast cancer patients with different S100A8 expression states was statistically significant(P<0.05).3.In the 93 samples in this study,the expression of ER,HER-2,Ki67 and S100A8 were s’ignificantly correlated(P<0.05),and the positive rate of S100A8 expression was higher in patients with negative ER,positive HER-2 and high expression of Ki67,but there was no significant correlation between the expression of PR and S100A8(P>0.05).In the comparison of molecular typing,there were 2 cases(2/15,13.3%)with positive expression of Luminal A type in 15 cases,14 cases(14/37,37.8%)with positive expression of Luminal B type in 37 cases,18 cases(14/32,43.8%)with positive expression of HER-2 overexpression in 32 cases,and 3 cases(3/9,33.3%)with positive expression of triple negative type in 9 cases.The expression of S100A8 was significantly different among different molecular types(P<0.05),and the expression rate of S100A8 in Luminal B type,HER-2 overexpression type and trinegative type was higher than that of Luminal A type.The positive expression of S100A8 was not significantly correlated with age,tumor size,lymph node metastasis and pathological stage(P>0.05).4.Multivariate analysis of the expression status of S100A8,ER,PR,HER-2 and Ki67,the clinical response rate of NAC in breast cancer(CR+PR)and PCR showed that high expression of S100A8 was an independent predictor of the clinical response rate of NAC in breast cancer(P=0.011,OR=4.550;95%CI:1.413-14.651),2.083 times higher than that of patients with low expression;S100A8 can also be used as an independent predictor of pCR rate.Conclusion1.S100A8 was significantly correlated with the clinical efficacy and pCR rate of neoadjuvant chemotherapy.2.S100A8 was not related to patient age,tumor size,lymph node metastasis or clinical stage.3.The expression of S100A8 was significantly correlated with ER,HER-2,Ki67 and the molecular typing of breast cancer,but not with the expression status of PR.4.High expression of S100A8 and Ki67 was an independent predictor of clinical response rate and pCR rate of NAC in breast cancer,while ER,PR and HER2 were not independent predictors of chemotherapy efficacy.